Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Purpura, Thrombocytopenic, Idiopathic 3

Interventions

pembrolizumab 41Carboplatin 38Cisplatin 34Paclitaxel 27Pemetrexed 23Gemcitabine 23Nivolumab 22Dexamethasone 17Ipilimumab 16Rituximab 15Fluorouracil 14Capecitabine 14Docetaxel 13trastuzumab deruxtecan 12durvalumab 12atezolizumab 12Cyclophosphamide 12Trastuzumab 11Lenalidomide 11olaparib 10130-nm albumin-bound paclitaxel 10Prednisone 9venetoclax 8daratumumab 8Oxaliplatin 8Cytarabine 8Bortezomib 8Bevacizumab 8zanubrutinib 7Vinorelbine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has announcements × fostamatinib × Clear all
NCT02077192 2023-12-11

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Rigel Pharmaceuticals

Phase 3 Completed
123 enrolled 11 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT02076399 2019-02-12

FIT

Rigel Pharmaceuticals

Phase 3 Completed
76 enrolled 17 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT02076412 2019-01-25

FIT

Rigel Pharmaceuticals

Phase 3 Completed
74 enrolled 17 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡